Cover Image
Market Research Report

Arteriosclerosis - Pipeline Review, H2 2014

Published by Global Markets Direct Product code 245965
Published Content info 59 Pages
Immediate Delivery Available
Price
Back to Top
Arteriosclerosis - Pipeline Review, H2 2014
Published: July 31, 2014 Content info: 59 Pages
Description

Summary

Global Markets Direct's, 'Arteriosclerosis - Pipeline Review, H2 2014', provides an overview of the Arteriosclerosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arteriosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arteriosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arteriosclerosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Arteriosclerosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Arteriosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Arteriosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Arteriosclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Arteriosclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Product Code: GMDHC5260IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arteriosclerosis Overview
  • Therapeutics Development
    • Pipeline Products for Arteriosclerosis - Overview
    • Pipeline Products for Arteriosclerosis - Comparative Analysis
  • Arteriosclerosis - Therapeutics under Development by Companies
  • Arteriosclerosis - Therapeutics under Investigation by Universities/Institutes
  • Arteriosclerosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Arteriosclerosis - Products under Development by Companies
  • Arteriosclerosis - Products under Investigation by Universities/Institutes
  • Arteriosclerosis - Companies Involved in Therapeutics Development
    • Johnson & Johnson
    • Kowa Company, Ltd.
    • Nippon Shinyaku Co., Ltd.
    • KunWha Pharmaceutical Co., Ltd.
    • AnGes MG, Inc.
    • LTT Bio-Pharma Co., Ltd.
    • CytoTools AG
  • Arteriosclerosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ecraprost - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-134 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selexipag - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarpogrelate SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LMW-0x - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-0101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VE-Statin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Arteriosclerosis - Recent Pipeline Updates
  • Arteriosclerosis - Dormant Projects
  • Arteriosclerosis - Discontinued Products
  • Arteriosclerosis - Product Development Milestones
    • Featured News & Press Releases
      • May 01, 2014: The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions
      • Nov 15, 2012: AtheroNova Receives Notice Of Issuance Of U.S. Patent 8,304,383
      • Nov 02, 2012: AlphaCore Receives Orphan Drug Designation For ACP-501 From European Medicines Agency
      • Aug 26, 2012: Merck Provides Update On Tredaptive Development Program
      • Jul 09, 2012: AtheroNova Receives Notice Of Allowance For US Patent Application 12/024,908
      • Apr 25, 2012: Frontage Signs Agreement For Development Of Clinical Trial Supplies
      • Nov 02, 2011: Resverlogix Commences Dosing In ASSURE Phase IIb IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
      • Mar 21, 2011: FDA Accepts Arisaph's Investigational New Drug Application For Dyslipidemia Drug
      • Jan 04, 2011: AnGes MG Announces Publication Of Collategene Clinical Research Data In Arteriosclerosis, Thrombosis And Vascular Biology
      • Jul 26, 2010: Cerenis And Novasep Receive EUR10.7 Million Funding From French Government For Development Of CER-001
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arteriosclerosis, H2 2014
  • Number of Products under Development for Arteriosclerosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Arteriosclerosis - Pipeline by Johnson & Johnson, H2 2014
  • Arteriosclerosis - Pipeline by Kowa Company, Ltd., H2 2014
  • Arteriosclerosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by KunWha Pharmaceutical Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by AnGes MG, Inc., H2 2014
  • Arteriosclerosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014
  • Arteriosclerosis - Pipeline by CytoTools AG, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Arteriosclerosis Therapeutics - Recent Pipeline Updates, H2 2014
  • Arteriosclerosis - Dormant Projects, H2 2014
  • Arteriosclerosis - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Arteriosclerosis, H2 2014
  • Number of Products under Development for Arteriosclerosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top